

10/583,046M\_S\_partial\_scope Yong Chu 09/22/2009

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssptaylc1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \*

|      |    |        |  |
|------|----|--------|--|
| NEWS | 1  |        | Web Page for STN Seminar Schedule - N. America   |
| NEWS | 2  | DEC 01 | ChemPort single article sales feature unavailable  |
| NEWS | 3  | JUN 01 | CAS REGISTRY Source of Registration (SR) searching enhanced on STN                             |
| NEWS | 4  | JUN 26 | NUTRACEUT and PHARMAML no longer updated   |
| NEWS | 5  | JUN 29 | IMSCOPROFILE now reloaded monthly  |
| NEWS | 6  | JUN 29 | EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields          |
| NEWS | 7  | JUL 09 | PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields |
| NEWS | 8  | JUL 14 | USGENE enhances coverage of patent sequence location (PSL) data                                |
| NEWS | 9  | JUL 27 | CA/CAplus enhanced with new citing references  |
| NEWS | 10 | JUL 16 | GBFULL adds patent backfile data to 1855   |
| NEWS | 11 | JUL 21 | USGENE adds bibliographic and sequence information   |
| NEWS | 12 | JUL 28 | EPFULL adds first-page images and applicant-cited references                                   |
| NEWS | 13 | JUL 28 | INPADOCDB and INPAFAMDB add Russian legal status data  |
| NEWS | 14 | AUG 10 | Time limit for inactive STN sessions doubles to 40 minutes                                     |
| NEWS | 15 | AUG 18 | COMPENDEX indexing changed for the Corporate Source (CS) field                                 |
| NEWS | 16 | AUG 24 | ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced   |
| NEWS | 17 | AUG 24 | CA/CAplus enhanced with legal status information for U.S. patents                              |
| NEWS | 18 | SEP 09 | 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY                                |
| NEWS | 19 | SEP 11 | WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus                                  |

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:01:31 ON 21 SEP 2009

FILE 'REGISTRY' ENTERED AT 11:01:46 ON 21 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2009 HIGHEST RN 1185847-75-9  
DICTIONARY FILE UPDATES: 20 SEP 2009 HIGHEST RN 1185847-75-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L15\_09222009.str



```

chain nodes :
1 2 3 4 5 7 8 9 13 14
chain bonds :
1-2 2-3 3-4 3-5 4-7 7-8 8-9 8-13 9-14
exact/norm bonds :
1-2 2-3 3-4 3-5 4-7 8-9 8-13 9-14
exact bonds :
7-8

```

Connectivity :

```
5:1 E exact RC ring/chain 13:1 E exact RC ring/chain
Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:CLASS 9:Atom 13:CLASS
14:Atom
```

```
Generic attributes :
```

```
1:
Saturation : Unsaturated
```


```
Element Count :
```

```
Node 9: Limited
N,N1
```

```
Node 14: Limited
N,N1
```

```
L1 STRUCTURE UPLOADED
```

```
=> d
L1 HAS NO ANSWERS
L1 STR
```



```
Structure attributes must be viewed using STN Express query preparation.
```

```
=> s l1
SAMPLE SEARCH INITIATED 11:02:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13725 TO ITERATE
```


```
14.6% PROCESSED 2000 ITERATIONS 6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 267480 TO 281520
PROJECTED ANSWERS: 438 TO 1208
```

```
L2 6 SEA SSS SAM L1
```

=> d scan

L2 6 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C27 H33 N5 O5 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

```
=> s 11 full
FULL SEARCH INITIATED 11:18:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 276530 TO ITERATE
```

100.0% PROCESSED 276530 ITERATIONS 682 ANSWERS  
SEARCH TIME: 00.00.06

L3 682 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 11:18:52 ON 21 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2009 VOL 151 ISS 13  
FILE LAST UPDATED: 20 Sep 2009 (20090920/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 13  
L4            20 L3

=> d ibib abs hitstr tot  
THE ESTIMATED COST FOR THIS REQUEST IS 112.80 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:288826 CAPLUS Full-text  
DOCUMENT NUMBER: 150:330127  
TITLE: Preparation of biphenyls and biheteroaryls end-capped with amino acid or peptide derivatives as hepatitis c virus inhibitors  
INVENTOR(S): Bachand, Carol; Belema, Makonen; Deon, Daniel H.; Good, Andrew C.; Goodrich, Jason; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Meanwell, Nicholas A.; Nguyen, Van N.; Romine, Jeffrey Lee; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Langley, David R.; Wang, Gan; Hamann, Lawrence G.  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: U.S. Pat. Appl. Publ., 515pp., Cont.-in-part of U.S. Ser. No. 835,462.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

| PATENT NO.             | KIND              | DATE     | APPLICATION NO. | DATE        |
|------------------------|-------------------|----------|-----------------|-------------|
| US 20090068140         | A1                | 20090312 | US 2008-30232   | 20080213    |
| US 20080050336         | A1                | 20080228 | US 2007-835462  | 20070808    |
| PRIORITY APPLN. INFO.: |                   |          | US 2007-835462  | A2 20070808 |
|                        |                   |          | US 2006-836996P | P 20060811  |
| OTHER SOURCE(S):       | MARPAT 150:330127 |          |                 |             |
| GI                     |                   |          |                 |             |

AB The invention is related to 4,4'-disubstituted biphenyls and biheteroaryls in which the substituents in 4 and 4' positions contain structures assocd. with amino acids and peptides, e.g., I, their pharmaceutical acceptable salts, pharmaceutical compns. and methods for the treatment of hepatitis C virus (HCV) infection. Thus, Pd-coupling of bromide II (prepn. given) with boronate III (prepn. given), hydrogenolysis, cleavage of the tert-butoxycarbonyl groups and coupling with N-(methoxycarbonyl)-L-valine gave I as an acetate salt. Compds. of the invention were active in an HCV replicon assay.

IT 1009113-10-3P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of biphenyls and biheteroaryls end-capped with amino acid or peptide derivs. as hepatitis c virus inhibitors)

RN 1009113-10-3 CAPLUS


CN Urea, N-[(1R)-2-oxo-1-phenyl-2-[(2S)-2-[5-[4'-(2-[(2S)-1-[(2R)-tetrahydro-2-furanyl]carbonyl]-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]ethyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 2008:220741 CAPLUS Full-text  
 DOCUMENT NUMBER: 148:308634  
 TITLE: Preparation of biphenyls and biheteroaryls end-capped with amino acid or peptide derivatives as hepatitis c virus inhibitors  
 INVENTOR(S): Bachand, Carol; Belema, Makonen; Deon, Daniel H.; Good, Andrew C.; Goodrich, Jason; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Meanwell, Nicholas A.; Nguyen, Van N.; Romine, Jeffrey Lee; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Langley, David R.; Wang, Gan; Hamann, Lawrence G.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 732pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2008021927   | A2   | 20080221 | WO 2007-US75544 | 20070809   |
| WO 2008021927   | A3   | 20080529 |                 |            |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |      |          |                 |            |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  |      |          |                 |            |
| US 20080050336  | A1   | 20080228 | US 2007-835462  | 20070808   |
| AU 2007286222   | A1   | 20080221 | AU 2007-286222  | 20070809   |
| CA 2660520  | A1   | 20080221 | CA 2007-2660520 | 20070809   |
| EP 2049522  | A2   | 20090422 | EP 2007-800058  | 20070809   |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS   |      |          |                 |            |
| NO 2009000447   | A    | 20090302 | NO 2009-447     | 20090129   |
| IN 2009DN00853  | A    | 20090612 | IN 2009-DN853   | 20090305   |
| KR 2009040909   | A    | 20090427 | KR 2009-704970  | 20090310   |
| PRIORITY APPLN. INFO.:  |      |          | US 2006-836996P | P 20060811 |
|   |      |          | US 2007-835462  | A 20070808 |
|   |      |          | WO 2007-US75544 | W 20070809 |

OTHER SOURCE(S): MARPAT 148:308634

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention is related to 4,4'-disubstituted biphenyls and biheteroaryls in which the substituents in 4 and 4' positions contain structures assocd. with amino acids and peptides, e.g. I, their pharmaceutical acceptable salts,

pharmaceutical compns. and methods for the treatment of hepatitis C virus (HCV) infection. Thus, Pd-coupling of bromide II (prepn. given) with boronate III (prepn. given), hydrogenolysis, cleavage of the tert-butoxycarbonyl groups and coupling with N-(methoxycarbonyl)-L-valine gave I as an acetate salt. Compds. of the invention were active in an HCV replicon assay.

IT 1009113-10-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of biphenyls and biheteroaryls end-capped with amino acid or peptide derivs. as hepatitis c virus inhibitors)

RN 1009113-10-3 CAPLUS


CN Urea, N-[(1R)-2-oxo-1-phenyl-2-[(2S)-2-[5-[4'-(2-[(2S)-1-[(2R)-tetrahydro-2-furanyl]carbonyl]-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]ethyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:1120606 CAPLUS Full-text  
DOCUMENT NUMBER: 147:406845

TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other conditions  
 INVENTOR(S): Chen, Ling; Chaturvedula, Prasad V.; Civiello, Rita; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham S.; Tora, George O.  
 PATENT ASSIGNEE(S): ~~Bristol-Myers Squibb Company, USA~~  
 SOURCE: U.S. Pat. Appl. Publ., 215pp., Cont.-in-part of U.S. Ser. No. 729,155.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE        |
|------------------------|------|----------|-----------------|-------------|
| US 20070232600         | A1   | 20071004 | US 2007-620291  | 20070105    |
| US 7314883             | B2   | 20080101 |                 |             |
| US 20040204397         | A1   | 20041014 | US 2003-729155  | 20031205    |
| US 7220862             | B2   | 20070522 |                 |             |
| PRIORITY APPLN. INFO.: |      |          | US 2003-729155  | A2 20031205 |
|                        |      |          | US 2002-386138P | P 20020605  |
|                        |      |          | US 2002-388617P | P 20020613  |
|                        |      |          | US 2002-389870P | P 20020619  |
|                        |      |          | US 2002-393200P | P 20020701  |
|                        |      |          | US 2002-413534P | P 20020925  |
|                        |      |          | US 2003-445523  | A2 20030527 |

OTHER SOURCE(S): MARPAT 147:406845  
GI



AB      Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prep'd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic

inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prep'd. from 1H-indazole-5-carboxaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .1toreq. 10 nM.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-92-1P  
 635711-93-2P 635711-94-3P 635711-95-4P  
 635711-96-5P 635711-97-6P 635711-98-7P  
 635711-99-8P 635712-00-4P 635712-01-5P  
 635712-02-6P 635712-04-8P 635712-05-9P  
 635712-08-2P 635712-09-3P 635712-10-6P  
 635712-11-7P 635712-12-8P 635712-13-9P  
 635712-14-0P 635712-15-1P 635712-16-2P  
 635712-17-3P 635712-19-5P 635712-20-8P  
 635712-22-0P 635712-23-1P 635712-24-2P  
 635712-25-3P 635712-26-4P 635712-27-5P  
 635712-28-6P 635712-29-7P 635712-30-0P  
 635712-31-1P 635712-32-2P 635712-33-3P  
 635712-34-4P 635712-35-5P 635712-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other diseases)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-( (1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)-(CA INDEX NAME)


## Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


## Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[ $(1S)$ -1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-(trifluoromethyl)phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[ $(1S)$ -1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidinyl)carbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidinyl)carbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[ $(1S)$ -1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[ $(1S)$ -1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(1-methylethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[ $(1S)$ -1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chloro-5-(trifluoromethyl)phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[ $(1S)$ -1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:845275 CAPLUS Full-text

DOCUMENT NUMBER: 147:227208

TITLE: Compositions and methods using matrix metalloproteinase (MMP) inhibitors for treating cognitive impairment characterized by persistent or sustained MMP expression and/or activity

INVENTOR(S): Harding, Joseph; Wright, John; Meighan, Peter; Meighan, Stala

PATENT ASSIGNEE(S): Washington State University Research Foundation, USA

SOURCE: PCT Int. Appl., 92pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2007087637   | A2   | 20070802 | WO 2007-US61167 | 20070126 |
| WO 2007087637   | A3   | 20071129 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,<br>KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,<br>MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,<br>RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,<br>TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW<br>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,<br>IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,<br>CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,<br>GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA |      |          |                 |          |

PRIORITY APPLN. INFO.: US 2006-762388P P 20060126

AB The invention provides methods for treating cognitive impairment, comprising administration of a therapeutically effective amt. of at least one matrix metalloproteinase (MMP) inhibitor sufficient to provide for at least one of precluding, alleviating, reversing, or inhibiting cognitive impairment characterized by sustained elevated expression and/or activity of at least one MMP. Persistent elevations in the expression of MMPs in the hippocampus of aged individuals have a detrimental effect on hippocampal synaptic plasticity, and are an underlying cause of cognitive deficits assocd. with ageing, and particular aspects therefore provide novel compns. and methods comprising use of MMP (e.g., MMP3 and/or MMP9, etc.) inhibitors to treat age-related cognitive impairment (e.g., cognitive decline). Addnl. embodiments comprise inhibition of MMP-3 and at least one other MMP (e.g., MMP-9, etc.). Exemplary MMP inhibitors comprise a zinc-binding hydroxamate moiety (or a non-hydroxamate zinc-binding moiety), and a peptide or peptidomimetic backbone capable of binding at least one MMP.

IT 198700-71-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitors for treating cognitive impairment, and use with other agents)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-([(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:705719 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 147:118256  
 TITLE: Preparation of piperidine-1-carboxamide derivatives and spirocycles thereof as antagonists of calcitonin gene-related peptide receptors  
 INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita;  
 Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun;  
 Jiang, Xiang Jun J.; Macor, John E.; Poindexter,  
 Graham S.; Tora, George O.; Luo, Guanglin  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: U.S. Pat. Appl. Publ., 198pp., Cont.-in-part of U.S.  
 Ser. No. 729,155.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE            |
|------------------------|------|----------|-----------------|-----------------|
| US 20070149503         | A1   | 20070628 | US 2007-620308  | 20070105        |
| US 20040204397         | A1   | 20041014 | US 2003-729155  | <u>20031205</u> |
| US 7220862             | B2   | 20070522 |                 |                 |
| PRIORITY APPLN. INFO.: |      |          | US 2003-729155  | A2 20031205     |
|                        |      |          | US 2002-386138P | P 20020605      |
|                        |      |          | US 2002-388617P | P 20020613      |
|                        |      |          | US 2002-389870P | P 20020619      |
|                        |      |          | US 2002-393200P | P 20020701      |
|                        |      |          | US 2002-413534P | P 20020925      |
|                        |      |          | US 2003-445523  | A2 20030527     |

OTHER SOURCE(S): MARPAT 147:118256  
 GI



AB The title compds. [I; V = N(R1)(R2) or OR4; R4 = H, C1-6 alkyl, C1-4 haloalkyl, etc.; R1, R2 = independently H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -C1-6alkyleneamino(C1-3alkyl)2, C3-7 cycloalkyl,

Ph, azetidinyl, adamantyl, tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, etc.; R1 and R2 optionally and independently contain 1 or 2 carbonyls or optionally and independently interrupted from the nitrogen to which C1-3 alkylene or C1-3 alkylidene; or NR1R2 together form each (un)substituted azetidinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, azepinyl, or diazepinyl, or spirocyclic ring, etc.; Q = (Sy)sR3, NH(Sy)sR3, NHC(O)(Sy)sR3, NHC(O)O(Sy)sR3, NHC(O)NH(Sy)sR3, O(Sy)sR3, (Sy)sNHR3, etc.; wherein Sy = C1-3 alkylene or C1-3 alkylidene; s = 0 or 1; U = CH<sub>2</sub>, NH; R3 = (i) heterocycle having two 5 to 7 membered fused rings, (ii) 4 to 6 membered heterocycle contg. 1-3 heteroatoms selected from O, N and S optionally contg. 1 to 2 carbonyls, (iii) C3-7 cycloalkyl, etc.; D = O, N(CN) or N(SO<sub>2</sub>-C1-3 alkyl); A = C; m, n = 1; E = N, CH, C; p = 0; G, J and E together form a fused heterocycle having two 5- to 7-membered fused rings optionally contg. 1 or 2 carbonyls] or pharmaceutically acceptable salts thereof are prepd. These compds. are antagonists of calcitonin gene-related peptide receptors (CGRP receptor) and are useful in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Thus, (R)-2-[[[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidin-1-yl]carbonyl]amino]-3-[1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indazol-5-yl]propionic acid was condensed with 4-piperidinopiperidine using PyBIO in CH<sub>2</sub>Cl<sub>2</sub> at room temp. for 16 h followed by treatment with CsF at 80.degree. in MeCN to give (R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidine-1-carboxylic acid [2-[1,4']bipiperidinyl-1'-yl-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]amide (II). II showed IC<sub>50</sub> of .1toreq.10 nM for inhibiting the binding of [<sup>125</sup>I]CGRP to homogenate of SK-NMC cells.

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 635711-71-6P | 635711-72-7P | 635711-73-8P |
|    | 635711-75-0P | 635711-76-1P | 635711-77-2P |
|    | 635711-78-3P | 635711-79-4P | 635711-80-7P |
|    | 635711-82-9P | 635711-83-0P | 635711-84-1P |
|    | 635711-86-3P | 635711-87-4P | 635711-88-5P |
|    | 635711-89-6P | 635711-90-9P | 635711-92-1P |
|    | 635711-93-2P | 635711-94-3P | 635711-95-4P |
|    | 635711-96-5P | 635711-97-6P | 635711-98-7P |
|    | 635711-99-8P | 635712-00-4P | 635712-01-5P |
|    | 635712-02-6P | 635712-04-8P | 635712-05-9P |
|    | 635712-08-2P | 635712-09-3P | 635712-10-6P |
|    | 635712-11-7P | 635712-12-8P | 635712-13-9P |
|    | 635712-14-0P | 635712-15-1P | 635712-16-2P |
|    | 635712-17-3P | 635712-19-5P | 635712-20-8P |
|    | 635712-22-0P | 635712-23-1P | 635712-24-2P |
|    | 635712-25-3P | 635712-26-4P | 635712-27-5P |
|    | 635712-28-6P | 635712-29-7P | 635712-30-0P |
|    | 635712-31-1P | 635712-32-2P | 635712-33-3P |
|    | 635712-34-4P | 635712-35-5P | 635712-38-8P |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidine-1-carboxamide derivs. and spirocyclic compds. thereof as antagonists of calcitonin gene-related peptide receptors)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidinyl-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-(*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-[trifluoromethyl]phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(1-methylethyl)phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[[[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[ (1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[ (1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-([(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:1157062 CAPLUS Full-text  
DOCUMENT NUMBER: 145:465769  
TITLE: MMPIs for treatment of TGF. $\beta$ .-induced subcapsular cataract formation  
INVENTOR(S): West-Mays, Judith  
PATENT ASSIGNEE(S): McMaster University, Can.  
SOURCE: PCT Int. Appl., 47pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2006113993   | A1   | 20061102 | WO 2006-CA661   | 20060428   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,<br>KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,<br>MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,<br>SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,<br>VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,<br>IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,<br>CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,<br>GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM  |      |          |                 |            |
| CA 2605783  | A1   | 20061102 | CA 2006-2605783 | 20060428   |
| EP 1877051  | A1   | 20080116 | EP 2006-721851  | 20060428   |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,<br>IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR  |      |          |                 |            |
| US 20080187572  | A1   | 20080807 | US 2008-912729  | 20080311   |
| PRIORITY APPLN. INFO.:  |      |          | US 2005-675443P | P 20050428 |
|   |      |          | WO 2006-CA661   | W 20060428 |

AB The invention provides novel methods and compns. for the treatment and/or prevention of cataracts. A compn. that inhibits destabilization of E-cadherin is administered. Preferably the compn. comprises a matrix metalloproteinase

inhibitor (MMPI). MMPI GM6001 exhibited dose-dependent attenuation of transforming growth factor .beta. (TGF.beta.)-induced cataract formation in an ex vivo rat lens model. The role of MMP-9 in TGF.beta.-induced anterior subcapsular cataract formation was investigated in a novel mouse MMP-9 knockout model.

IT 198700-79-7 198700-79-7D, analogs or derivs.


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(MMPIs for treatment of TGF.beta.-induced subcapsular cataract formation)

RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:558817 CAPLUS Full-text

DOCUMENT NUMBER: 145:63142

TITLE: Preparation of amino acid urea derivatives as factor Xa inhibitors

INVENTOR(S): Song, Yonghong; Zhu, Bing-Yan; Wang, Shumei; Bhakta, Chhaya; Scarborough, Robert M.

PATENT ASSIGNEE(S): Portola Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND   | DATE     | APPLICATION NO. | DATE     |
|---|--|----------|-----------------|----------|
| WO 2006063113   | A2   | 20060615 | WO 2005-US44388 | 20051207 |
| WO 2006063113   | A3   | 20070510 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,<br>KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,<br>MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,<br>SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,<br>VN, YU, ZA, ZM, ZW | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,<br>IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, FR, BF, BJ,<br>CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,<br>GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA |          |                 |          |
| US 20060160821  | A1   | 20060720 | US 2005-298317  | 20051207 |

PRIORITY APPLN. INFO.: US 2004-634201P P 20041207

OTHER SOURCE(S): CASREACT 145:63142; MARPAT 145:63142


AB The invention relates to urea derivs. A-Q-D-(CR7R8)<sub>m</sub>(NR6)<sub>n</sub>COCR4R5NR3CONR1R2 [m, n are 0 or 1; D is a direct bond, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heteromonocyclyl, heterobicyclyl; Q is a direct bond, alkylene, CO, CS, O, S, imino, SO<sub>2</sub>, SO, etc. (at least one of D and Q is not a direct bond); A is amino, amidino, guanidino groups, alkyl, pyridyl oxide, etc.; R1 is H, alkyl, arylalkyl, heteroaryl, alkenyl; R2 is (un)substituted arylalkyl, arylcycloalkyl, heteroaryl, cycloalkyl, etc.; R3-R8 are H, (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or R4 may from a ring with R5 or R6] and their pharmaceutically-acceptable salts and prodrugs which are inhibitors of Factor Xa and are used to prevent or treat a no. of conditions characterized by undesired thrombosis. Thus, N-[(4-chlorophenyl)amino]carbonyl]glycine [4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]amide was prep'd. by reaction of Boc-protected glycine with 4-aminobenzonitrile, iodomethane, N-methylethylenediamine, and 4-chlorophenyl isocyanate. The product showed IC50 .ltoreq. 100 nM for inhibition of factor Xa.

IT 891789-82-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of amino acid urea derivs. as factor Xa inhibitors)

RN 891789-82-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2-[4-(hexahydro-1H-azepin-4-yl)-1-piperazinyl]-1-(2-methoxyphenyl)-2-oxoethyl)- (CA INDEX NAME)



IT 855524-53-7P 891789-13-2P 891789-21-2P  
 891789-34-7P 891789-39-2P 891789-48-3P  
 891789-57-4P 891789-58-5P 891789-71-2P  
 891789-72-3P 891789-73-4P 891789-74-5P  
 891789-75-6P 891789-76-7P 891789-77-8P  
 891789-78-9P 891789-79-0P 891789-80-3P  
 891789-81-4P 891789-83-6P 891789-84-7P  
 891789-85-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino acid urea derivs. as factor Xa inhibitors)

RN 855524-53-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 891789-13-2 CAPLUS

CN Urea, N-[1-(2-bromophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 891789-21-2 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1-(2-methylphenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 891789-34-7 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 891789-39-2 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1-(2-methoxyphenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 891789-48-3 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1-(2-iodophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)



RN 891789-57-4 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1-(2-fluorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 891789-58-5 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl)- (CA INDEX NAME)




RN 891789-71-2 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)-1-phenylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891789-72-3 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]-1-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 891789-73-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-oxo-2-[4-(2-oxo-1(2H)-pyridinyl)-1-piperidinyl]-1-phenylethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 891789-74-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-fluorophenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl)- (CA INDEX NAME)




RN 891789-75-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-chlorophenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl)- (CA INDEX NAME)




RN 891789-76-7 CAPLUS

CN Urea, N-[1-(2-bromophenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 891789-77-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-methylphenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl)- (CA INDEX NAME)




RN 891789-78-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-methoxyphenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl)- (CA INDEX NAME)




RN 891789-79-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-fluorophenyl)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)ethyl)- (CA INDEX NAME)




RN 891789-80-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-methoxyphenyl)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)ethyl)-(CA INDEX NAME)




RN 891789-81-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(2-methoxyphenyl)-2-[4-(4-methyl-2-oxo-1-piperazinyl)-1-piperidinyl]-2-oxoethyl)-(CA INDEX NAME)



RN 891789-83-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(2-[4-(hexahydro-1-methyl-1H-azepin-4-yl)-1-piperazinyl]-1-(2-methoxyphenyl)-2-oxoethyl)-(CA INDEX NAME)



RN 891789-84-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxo-1-phenylethyl)-(CA INDEX NAME)

Absolute stereochemistry.



RN 891789-85-8 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[hexahydro-4-(1-methyl-4-piperidinyl)-1H-1,4-diazepin-1-yl]-2-oxo-1-phenylethyl]-(CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:638773 CAPLUS Full-text  
DOCUMENT NUMBER: 143:133401  
TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists  
INVENTOR(S): Degnan, Andrew P.; Chen, Ling; Civiello, Rita; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Macor, John E.; Tora, George  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: PCT Int. Appl., 385 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO.  | DATE     |
|--|------|----------|------------------|----------|
| WO 2005065779  | A1   | 20050721 | WO 2003-US38799  | 20031205 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,<br>LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,<br>NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,<br>TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |          |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,<br>BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,<br>ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,<br>TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |          |
| CA 2549330   | A1   | 20050721 | CA 2003-2549330  | 20031205 |
| AU 2003297694  | A1   | 20050812 | AU 2003-297694   | 20031205 |
| EP 1689493   | A1   | 20060816 | EP 2003-819270   | 20031205 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                  |          |
| BR 2003018637  | A    | 20070213 | BR 2003-18637    | 20031205 |
| CN 1917921   | A    | 20070221 | CN 2003-80111030 | 20031205 |

|                        |   |          |                  |             |
|------------------------|---|----------|------------------|-------------|
| JP 2007524568          | T | 20070830 | JP 2005-513137   | 20031205    |
| TW 284534              | B | 20070801 | TW 2004-93137052 | 20041201    |
| IN 2006DN02822         | A | 20070803 | IN 2006-DN2822   | 20060518    |
| MX 2006006070          | A | 20060719 | MX 2006-6070     | 20060529    |
| ZA 2006004503          | A | 20071128 | ZA 2006-4503     | 20060601    |
| NO 2006002648          | A | 20060802 | NO 2006-2648     | 20060608    |
| KR 2006125832          | A | 20061206 | KR 2006-713470   | 20060704    |
| PRIORITY APPLN. INFO.: |   |          | EP 2003-819270   | TO 20031205 |
|                        |   |          | WO 2003-US38799  | W 20031205  |

OTHER SOURCE(S): MARPAT 143:133401  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prep'd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). E.g., a multi-step synthesis of II which had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .ltoreq. 10 nM, was given. The pharmaceutical compn. comprising the compd. I is claimed.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-92-1P  
 635711-93-2P 635711-94-3P 635711-95-4P  
 635711-96-5P 635711-97-6P 635711-98-7P  
 635711-99-8P 635712-00-4P 635712-01-5P  
 635712-02-6P 635712-04-8P 635712-05-9P  
 635712-08-2P 635712-09-3P 635712-10-6P  
 635712-11-7P 635712-12-8P 635712-13-9P  
 635712-14-0P 635712-15-1P 635712-16-2P  
 635712-17-3P 635712-19-5P 635712-20-8P  
 635712-22-6P 635712-23-1P 635712-24-2P  
 635712-25-3P 635712-26-4P 635712-27-5P  
 635712-28-6P 635712-29-7P 635712-30-0P  
 635712-31-1P 635712-32-2P 635712-33-3P  
 635712-34-4P 635712-35-5P 635712-36-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-(*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(trifluoromethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(1-methylethyl)phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[[[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[ (1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[ (1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-([(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-(trifluoromethoxy)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
 (5 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:564638 CAPLUS Full-text  
 DOCUMENT NUMBER: 143:97382  
 TITLE: Preparation of urea derivatives as activated blood coagulation factor X (FXa) inhibitors  
 INVENTOR(S): Kubo, Keiji; Imaeda, Yasuhiro  
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan  
 SOURCE: PCT Int. Appl., 236 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent \*\*Current app\*\*  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE       |
|--|------|----------|-----------------|------------|
| WO 2005058823  | A1   | 20050630 | WO 2004-JP18717 | 20041215   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,<br>LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,<br>NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,<br>TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,<br>AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CA, CZ, DE, DK,<br>EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,<br>RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,<br>MR, NE, SN, TD, TG   |      |          |                 |            |
| CA 2550012   | A1   | 20050630 | CA 2004-2550012 | 20041215   |
| EP 1695961   | A1   | 20060830 | EP 2004-807076  | 20041215   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS   |      |          |                 |            |
| US 20070093501   | A1   | 20070426 | US 2006-583046  | 20060615   |
| PRIORITY APPLN. INFO.:   |      |          | JP 2003-420031  | A 20031217 |
|  |      |          | WO 2004-JP18717 | W 20041215 |

OTHER SOURCE(S): MARPAT 143:97382  
 GI



AB The title compds. I [Cy represents an optionally substituted arom. hydrocarbon group or optionally substituted arom. heterocyclic group; R1 represents hydrogen or an optionally substituted hydrocarbon group; V represents C(O), S(O), or S(O)2; W represents N(R2), O, or a bond (R2 represents hydrogen or an optionally substituted hydrocarbon group); X represents optionally substituted alkylene; Y represents C(O), S(O), or S(O)2; Z represents a bond, an optionally substituted chain hydrocarbon group, etc. ; ring A represents an optionally substituted nonarom. nitrogenous heterocycle; ring B represents an optionally substituted nitrogenous heterocycle; and the dotted line indicates a single bond or double bond; provided that R1 may be bonded to R2 to form an optionally substituted nonarom. nitrogenous heterocycle and that R2 may be bonded to a substituent of X to form an optionally substituted nonarom. nitrogenous heterocycle] are prepd. Thus, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-((3-(3-oxo-1H-imidazo[1,5-a]imidazol-2(3H)-yl)-1-pyrrolidinyl)carbonylpropyl)urea was prepd. in several steps from 1-benzyl-3-pyrrolidinamine and imidazole-2-carbaldehyde. Compds. of this invention in vitro showed IC<sub>50</sub> values of 10 nM to 50 nM against FXa. Formulations are given.

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 856415-69-5P | 856415-70-8P | 856415-72-0P |
|    | 856415-74-2P | 856415-75-3P | 856415-76-4P |
|    | 856415-77-8P | 856415-78-6P | 856415-79-7P |
|    | 856415-80-0P | 856415-81-1P | 856415-82-2P |
|    | 856415-83-3P | 856415-85-5P | 856415-86-6P |
|    | 856415-87-7P | 856415-88-8P | 856415-89-9P |
|    | 856415-90-2P | 856415-91-3P | 856415-92-4P |
|    | 856415-93-5P | 856415-94-6P | 856415-95-7P |
|    | 856415-96-8P | 856415-97-9P | 856415-98-0P |
|    | 856416-00-7P | 856416-01-8P | 856416-02-9P |
|    | 856416-03-0P | 856416-04-1P | 856416-05-2P |
|    | 856416-06-3P | 856416-07-4P | 856416-08-5P |
|    | 856416-09-6P | 856416-10-9P | 856416-11-0P |
|    | 856416-12-1P | 856416-13-2P | 856416-14-3P |
|    | 856416-15-4P | 856416-16-5P | 856416-17-6P |
|    | 856416-18-7P | 856416-19-8P | 856416-22-3P |
|    | 856416-23-4P | 856416-24-5P | 856416-25-6P |
|    | 856416-26-7P | 856416-27-8P | 856416-28-9P |
|    | 856416-29-0P | 856416-30-3P | 856416-31-4P |
|    | 856416-32-5P | 856416-33-6P | 856416-34-7P |
|    | 856416-35-8P | 856416-36-9P | 856416-37-0P |
|    | 856416-38-1P | 856416-39-2P | 856416-40-5P |
|    | 856416-41-6P | 856416-42-7P | 856416-43-8P |
|    | 856416-44-9P | 856416-45-0P | 856416-46-1P |
|    | 856416-47-2P | 856416-48-3P | 856416-51-8P |
|    | 856416-52-9P | 856416-53-0P | 856416-54-1P |
|    | 856416-56-3P | 856416-57-4P | 856416-58-5P |
|    | 856416-59-6P | 856416-60-9P | 856416-61-0P |
|    | 856416-62-1P | 856416-63-2P | 856416-68-7P |
|    | 856416-69-8P | 856416-70-1P | 856416-71-2P |
|    | 856416-72-3P | 856416-73-4P | 856416-74-5P |
|    | 856416-75-6P | 856416-82-5P | 856416-83-6P |


856416-84-7P    856416-85-8P    856416-86-9P  
 856416-87-0P    856416-88-1P    856416-89-2P  
 856416-90-5P    856416-91-6P    856416-92-7P  
 856416-93-8P    856416-94-9P    856416-95-0P  
 856416-96-1P    856416-97-2P    856416-98-3P  
 856416-99-4P    856417-00-0P    856417-01-1P  
 856417-02-2P    856417-07-7P    856417-08-8P  
 856419-82-4P    856419-83-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea derivs. as activated blood coagulation factor X inhibitors)


RN 856415-69-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)




RN 856415-70-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)




RN 856415-72-0 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-3-oxo-2-phenylpropyl]- (CA INDEX NAME)




RN 856415-74-2 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 856415-75-3 CAPLUS  
CN Urea, N'-(4-chlorophenyl)-N-methyl-N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 856415-76-4 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)



RN 856415-77-5 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-78-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-79-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-80-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1S)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-81-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-82-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1S)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-83-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-methyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-85-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-86-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-87-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-88-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-3-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-89-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-90-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-91-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R,2S)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-92-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R,2S)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856415-93-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-cyclopropyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 856415-94-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-cyclopropyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 856415-95-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2-ethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl)- (CA INDEX NAME)



RN 856415-96-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2-ethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]butyl)- (CA INDEX NAME)




RN 856415-97-9 CAPLUS

CN 1-Piperazinepropanoic acid, .alpha.-[[[(4-


chlorophenyl)amino]carbonyl]amino]-4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-.beta.-oxo-, methyl ester, (.alpha.R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856415-98-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-(methoxymethyl)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 856416-00-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-cyclopentyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)



RN 856416-01-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1-(ethoxymethyl)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl)- (CA INDEX NAME)



RN 856416-02-9 CAPLUS


CN Urea, N'-(4-chlorophenyl)-N-methyl-N-[(1R)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-03-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-hydroxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-04-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-hydroxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-05-2 CAPLUS

CN Urea, N-[2-[ (aminocarbonyl)oxy]-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 856416-06-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-ethyl-2-hydroxy-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl]- (CA INDEX NAME)



RN 856416-07-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-ethyl-2-hydroxy-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]butyl]- (CA INDEX NAME)



RN 856416-08-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-09-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(methylsulfinyl)propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-10-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(methylsulfonyl)propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-11-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2-(methylthio)propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-12-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-methyl-1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2-(methylsulfinyl)propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-13-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-methyl-1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2-(methylsulfonyl)propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-14-3 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1S)-2-[(2-methoxyethyl)thio]-2-methyl-1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-15-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-methyl-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)




RN 856416-16-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-methyl-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)




RN 856416-17-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxo-1-phenylpropyl]- (CA INDEX NAME)




RN 856416-18-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-3-oxo-1-phenylpropyl]- (CA INDEX NAME)




RN 856416-19-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2,2-dimethyl-1-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]propyl]- (CA INDEX NAME)




RN 856416-22-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-23-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 856416-24-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 856416-25-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[{(1R)-1-[(4-cyanophenyl)methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl}- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-26-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[{(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-[(4-phenylmethoxy)phenyl]methyl}ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-27-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'[(1R)-1-[(4-hydroxyphenyl)methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-28-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(3-pyridinylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-29-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(4-pyridinylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-30-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(2-thienylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-31-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-32-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonylbutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-33-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonylpentyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-34-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-cyclohexyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-35-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-cyclohexyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-36-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-3-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-37-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-3-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-38-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-3-(methylsulfinyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-39-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-3-(methylsulfonyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-40-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(phenylmethoxy)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-41-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-hydroxy-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-42-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)- (CA INDEX NAME)




RN 856416-43-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1-(1-hydroxycyclohexyl)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl)- (CA INDEX NAME)




RN 856416-44-9 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(2-methoxy-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl)propyl- (CA INDEX NAME)




RN 856416-45-0 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(2-methoxy-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl)propyl- (CA INDEX NAME)



RN 856416-46-1 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(2-ethoxy-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl)propyl- (CA INDEX NAME)




RN 856416-47-2 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(2-ethoxy-2-methyl-1-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl)propyl- (CA INDEX NAME)




RN 856416-48-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(3-methoxy-2,2-dimethyl-1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl)- (CA INDEX NAME)




RN 856416-51-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]pentyl)- (CA INDEX NAME)




RN 856416-52-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2-methyl-1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl)- (CA INDEX NAME)




RN 856416-53-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2,2-dimethyl-1-[(4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl)- (CA INDEX NAME)



RN 856416-54-1 CAPLUS


CN Urea, N-(4-chlorophenyl)-N-methyl-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 856416-56-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[3-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-pyrrolidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-57-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[3-(3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-pyrrolidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-58-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5,7-dimethyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-59-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(7-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-60-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(5,7-dimethyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2,2-dimethylpropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-61-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-[[4-(7,8-dihydro-1-methyl-5-oxoimidazo[1,5-c]pyrimidin-6(5H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-62-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-[[4-(7,8-dihydro-3-methyl-5-oxoimidazo[1,5-c]pyrimidin-6(5H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-63-2 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-1-[[4-(7,8-dihydro-5-oxoimidazo[1,5-c]pyrimidin-6(5H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-68-7 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]propyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-69-8 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[2-oxo[1,4'-bipiperidin]-1'-yl]carbonyl]propyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856416-70-1 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]carbonyl]propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-71-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(2-oxo-1-imidazolidinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-72-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(3-methyl-2-oxo-1-imidazolidinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-73-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(4-methyl-2-oxo-1-piperazinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-74-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]carbonylpropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-75-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[4-(1,1-dioxido-2-isothiazolidinyl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-82-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(2-methylimidazo[1,2-a]pyridin-5-yl)-1-piperazinyl]-2-oxo-1-phenylethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-83-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-([(1R)-2,2-dimethyl-1-[4-(2-methylimidazo[1,2-a]pyridin-5-yl)-1-piperazinyl]carbonyl]propyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-84-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-([(1R)-2,2-dimethyl-1-[4-(2-methyl-4-pyridinyl)-1-piperazinyl]carbonyl]propyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-85-8 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-phenyl- (CA INDEX NAME)




RN 856416-86-9 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-(4-methylphenyl)- (CA INDEX NAME)




RN 856416-87-0 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-88-1 CAPLUS


CN Urea, N-(4-fluorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-89-2 CAPLUS  
CN Urea, N-(4-bromophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-90-5 CAPLUS  
CN Urea, N-(4-cyanophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 856416-91-6 CAPLUS  
CN Urea, N-(3-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-92-7 CAPLUS  
CN Urea, N-(2-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-93-8 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 856416-94-9 CAPLUS

CN Urea, N-(4-chloro-2-methylphenyl)-N'-(2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl)- (CA INDEX NAME)



RN 856416-95-0 CAPLUS


CN Urea, N-(2,4-dichlorophenyl)-N'-(2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl)- (CA INDEX NAME)



RN 856416-96-1 CAPLUS


CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-

piperidinyl]-2-oxo-1-phenylethyl]-N'-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 856416-97-2 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-(4-(methylsulfinyl)phenyl)- (CA INDEX NAME)




RN 856416-98-3 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-(4-(methylsulfonyl)phenyl)- (CA INDEX NAME)




RN 856416-99-4 CAPLUS

CN Benzoic acid, 4-[[[[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 856417-00-0 CAPLUS

CN Urea, N-(5-chloro-2-pyridinyl)-N'-(2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl)- (CA INDEX NAME)




RN 856417-01-1 CAPLUS

CN Urea, N-(6-chloro-3-pyridinyl)-N'-(2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl)- (CA INDEX NAME)



RN 856417-02-2 CAPLUS


CN Urea, N-(5-chloro-2-pyrimidinyl)-N'-(2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl)- (CA INDEX NAME)



RN 856417-07-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[(4-[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-5-thiazolyl]-1-piperidinyl)carbonyl]-2,2-dimethylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 856417-08-8 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-5-thiazolyl]-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 856419-82-4 CAPLUS  
CN Urea, N-[(1R)-2,2-dimethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]-N'-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 856419-83-5 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-[[4-[5-(hydroxymethyl)-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:540568 CAPLUS Full-text  
DOCUMENT NUMBER: 143:78086  
TITLE: Preparation of urea/carbamate derivatives as  
inhibitors of coagulation factor Xa for treatment of  
thromboembolic disorders  
INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner;  
Tsaklakidis, Christos; Gleitz, Johannes  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 80 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO.  | DATE     |
|--|------|----------|------------------|----------|
| WO 2005056528  | A1   | 20050623 | WO 2004-EP13202  | 20041119 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, EZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,<br>LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,<br>NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,<br>TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br>RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,<br>AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,<br>EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,<br>SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,<br>NE, SN, TD, TG |      |          |                  |          |
| DE 10358539  | A1   | 20050707 | DE 2003-10358539 | 20031215 |
| AU 2004296956  | A1   | 20050623 | AU 2004-296956   | 20041119 |
| CA 2549548   | A1   | 20050623 | CA 2004-2549548  | 20041119 |
| EP 1694643   | A1   | 20060830 | EP 2004-820053   | 20041119 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS   |      |          |                  |          |
| CN 1890216   | A    | 20070103 | CN 2004-80036500 | 20041119 |
| BR 2004017153  | A    | 20070306 | BR 2004-17153    | 20041119 |
| JP 2007513987  | T    | 20070531 | JP 2006-544246   | 20041119 |
| IN 2006KN01578   | A    | 20070504 | IN 2006-KN1578   | 20060608 |
| MX 2006006593  | A    | 20060731 | MX 2006-6593     | 20060609 |

|                        |             |                                      |                       |
|------------------------|-------------|--------------------------------------|-----------------------|
| KR 2006123305          | A 20061201  | KR 2006-711538                       | 20060612              |
| US 20070123509         | A1 20070531 | US 2006-582850                       | 20060614              |
| ZA 2006005839          | A 20071031  | ZA 2006-5839                         | 20060714              |
| PRIORITY APPLN. INFO.: |             | DE 2003-10358539                     | <del>A 20031215</del> |
|                        |             | WO 2004-EP13202                      | W 20041119            |
| OTHER SOURCE(S):       |             | CASREACT 143:78086; MARPAT 143:78086 |                       |
| GI                     |             |                                      |                       |



- AB Title compds. I [D = halo, alkoxy, etc.; X = amino, O; Y = O, S, amino, etc.; R1 = H, aryl, heteroaryl, etc.; E = CH, N; Z, Z' = acyl, etc.; Q = O, amino, acyl, etc.; R4-4' = A, OH, alkoxy; T = (hetero)cyclyl, etc.] are prep'd. For instance, (R)-N-(4-chlorophenyl)-N'-(2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl)urea (II) is prep'd. in 3 steps from 1-methyl-4,4'-bipiperidinyl, (R)-N-(tert-butoxycarbonyl)phenylglycine and 4-chlorophenylisocyanate. II has IC50 = 6 x 10<sup>-9</sup> M for Factor Xa. I are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or the treatment of thromboembolic diseases and for treating tumors.
- IT 855524-53-7P, (R)-N-(4-Chlorophenyl)-N'-(2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl)urea 855524-59-3P,  
(R)-N-(4-Chlorophenyl)-N'-(2-oxo-1-phenyl-2-(4-(pyridin-4-yl)piperazin-1-yl)ethyl)urea 855524-60-6P 855524-62-8P  
855524-64-0P 855524-68-4P 855524-70-8P  
855524-72-0P 855524-73-1P,  
(R)-N-(4-Chlorophenyl)-N'-(1-(4-(pyridin-4-yl)piperazin-1-yl)carbonyl)butylurea 855524-78-6P,  
(R)-N-(4-Chlorophenyl)-N'-(2-oxo-1-phenyl-2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)urea 855524-81-1P,  
(R)-N-(4-Chlorophenyl)-N'-(2-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-2-oxo-1-phenylethyl)urea 855524-83-3P  
855524-84-4P 855524-88-8P 855524-89-9P,  
(R)-N-(2-([4,4'])Bipiperidinyl-1-yl)-2-oxo-1-phenylethyl)-(4-chlorophenyl)urea hydrochloride 855524-90-2P,  
(R)-N-(2-([4,4'])Bipiperidinyl-1-yl)-1-(4-hydroxyphenyl)-2-oxoethyl)-N'-(4-chlorophenyl)urea hydrochloride 855524-91-3P,  
(R)-N-(2-([4,4'])Bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea hydrochloride 855524-93-5P,  
(R)-N-(4-Chlorophenyl)-N'-(1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl)urea trifluoroacetate  
855524-95-7P, (R)-N-(4-Chlorophenyl)-N'-(2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl)urea trifluoroacetate  
855524-97-9P, (R)-N-(4-Chlorophenyl)-N'-(1-(4-hydroxyphenyl)-2-(4-morpholin-4-yl)piperidin-1-yl)-2-oxoethyl)urea trifluoroacetate  
855524-98-0P, N-[2-([1,4'])Bipiperidinyl-1'-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)urea 855525-00-7P,  
(R)-N-(4-Chlorophenyl)-N'-(2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxo-1-phenylethyl)urea trifluoroacetate 855525-02-9P,  
(R)-N-(2-([1,4'])Bipiperidinyl-1'-yl)-2-oxo-1-phenylethyl)-N'-(4-chlorophenyl)urea trifluoroacetate 855525-08-5P  
855525-10-9P 855525-12-1P,  
(R)-N-(4-Chlorophenyl)-N'-(2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxo-1-

(thiophen-2-yl)ethyl]urea trifluoroacetate 855525-14-3P,  
(R)-N-(2-([1,4']Bipiperidinyl-1'-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea trifluoroacetate 855525-18-7P  
855525-19-8P, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-[4,4']bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea  
855525-20-1P, (R)-N-(4-Chlorophenyl)-N'-[2-([4,4']bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea 855525-21-2P  
855525-22-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromboembolic disorders)

RN 855524-53-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-59-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855524-60-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-59-3


CMF C24 H24 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 855524-62-8 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 855524-61-7  
CMF C25 H32 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 855524-64-0 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(4-ethyl-1-piperazinyl)-1-piperidinyl]-2-oxo-1-phenylethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-63-9

CMF C26 H34 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-68-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R,2R)-2-methoxy-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]propyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-67-3

CMF C21 H26 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-70-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R,2R)-2-methoxy-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonylpropyl-, 2,2,2-trifluoroacetate (1:2)  
(CA INDEX NAME)

CM 1

CRN 855524-69-5

CMF C22 H34 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-72-0 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[ (1R, 2R)-2-methoxy-1-[ (1'-methyl[4,4'-bipiperidin]-1-yl)carbonyl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-71-9

CMF C23 H35 Cl N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 855524-73-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-1-[ [4-(4-pyridinyl)-1-piperazinyl]carbonyl]butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-78-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-81-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(4,6-dimethyl-2-pyrimidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-83-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S,2S)-2-hydroxy-1-[4-(4-pyridinyl)-1-piperazinyl]carbonyl]propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-84-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1S,2S)-2-hydroxy-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]propyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 855524-88-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R,2R)-1-[4-(4-ethyl-1-piperazinyl)-1-piperidinyl]carbonyl]-2-methoxypropyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-87-7

CMF C23 H36 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 855524-89-9 CAPLUS

CN Urea, N-[ (1R)-2-[ 4, 4'-bipiperidin]-1-yl-2-oxo-1-phenylethyl]-N'-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 855524-90-2 CAPLUS

CN Urea, N-[ (1R)-2-[ 4, 4'-bipiperidin]-1-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 855524-91-3 CAPLUS

CN Urea, N-[ (1R)-2-[ 4, 4'-bipiperidin]-1-yl-2-oxo-1-(2-thienyl)ethyl]-N'-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 855524-93-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-(4-hydroxyphenyl)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-92-4

CMF C26 H33 Cl N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-95-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-(2-thienyl)ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-94-6

CMF C24 H31 Cl N4 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-97-9 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-(4-hydroxyphenyl)-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-96-8


CMF C24 H29 Cl N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 855524-98-0 CAPLUS  
CN Urea, N-[2-[1,4'-bipiperidin]-1'-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 855525-00-7 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-'-[(1R)-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxo-1-phenylethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 855524-99-1  
CMF C24 H29 Cl N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 855525-02-9 CAPLUS


CN Urea, N-[ (1R)-2-[1,4'-bipiperidin]-1'-yl-2-oxo-1-phenylethyl]-N'-(4-chlorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-01-8

CMF C25 H31 Cl N4 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855525-08-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-1-(4-hydroxyphenyl)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-07-4


CMF C25 H32 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 855525-10-9 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxo-1-phenylethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 855525-09-6  
CMF C25 H32 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 855525-12-1 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxo-1-(2-thienyl)ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-11-0

CMF C22 H27 Cl N4 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855525-14-3 CAPLUS


CN Urea, N-[1R)-2-[1,4'-bipiperidin]-1'-yl-2-oxo-1-(2-thienyl)ethyl]-N'-(4-chlorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-13-2


CMF C23 H29 Cl N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 855525-18-7 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxo-1-(2-thienyl)ethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 855525-17-6  
CMF C23 H30 Cl N5 O2 S

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 855525-19-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-(2-chlorophenyl)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855525-20-1 CAPLUS

CN Urea, N-[1R)-2-[4,4'-bipiperidin]-1-yl-1-(2-chlorophenyl)-2-oxoethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 855525-21-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-1-(2-chlorophenyl)-2-(1'-methyl-2'-oxo[4,4'-bipiperidin]-1-yl)-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855525-22-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(1R)-2-(1'-methyl-2'-oxo[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:857166 CAPLUS Full-text

DOCUMENT NUMBER: 141:332218

TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists

INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Tora, George; Vig, Shikha

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. No. 445,523.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


| PATENT NO.     | KIND | DATE     | APPLICATION NO. | DATE     |
|----------------|------|----------|-----------------|----------|
| US 20040204397 | A1   | 20041014 | US 2003-729155  | 20031205 |
| US 7220862     | B2   | 20070522 |                 |          |
| US 20040063735 | A1   | 20040401 | US 2003-445523  | 20030527 |
| ZA 2004009654  | A    | 20060726 | ZA 2004-9654    | 20041129 |
| US 20070148093 | A1   | 20070628 | US 2006-641974  | 20061219 |

|                |    |          |                |          |
|----------------|----|----------|----------------|----------|
| US 20070149502 | A1 | 20070628 | US 2007-620253 | 20070105 |
| US 20070149503 | A1 | 20070628 | US 2007-620308 | 20070105 |
| US 20070232600 | A1 | 20071004 | US 2007-620291 | 20070105 |
| US 7314883     | B2 | 20080101 |                |          |

PRIORITY APPLN. INFO.:

|                 |             |
|-----------------|-------------|
| US 2002-386138P | P 20020605  |
| US 2002-388617P | P 20020613  |
| US 2002-389870P | P 20020619  |
| US 2002-393200P | P 20020701  |
| US 2002-413534P | P 20020925  |
| US 2003-445523  | A2 20030527 |
| US 2003-729155  | A3 20031205 |

OTHER SOURCE(S): MARPAT 141:332218  
GI



AB      Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prep'd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assoc'd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prep'd. from 1H-indazole-5-carboxaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .1toreq. 10 nM. The pharmaceutical compn. comprising the compd. I is claimed.

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 635711-71-6P | 635711-72-7P | 635711-73-8P |
|    | 635711-75-0P | 635711-76-1P | 635711-77-2P |
|    | 635711-78-3P | 635711-79-4P | 635711-80-7P |
|    | 635711-82-9P | 635711-83-0P | 635711-84-1P |
|    | 635711-86-3P | 635711-87-4P | 635711-88-5P |
|    | 635711-89-6P | 635711-90-9P | 635711-92-1P |
|    | 635711-93-2P | 635711-94-3P | 635711-95-4P |
|    | 635711-96-5P | 635711-97-6P | 635711-98-7P |
|    | 635711-99-8P | 635712-00-4P | 635712-01-5P |
|    | 635712-02-6P | 635712-04-8P | 635712-05-9P |
|    | 635712-08-2P | 635712-09-3P | 635712-10-6P |
|    | 635712-11-7P | 635712-12-8P | 635712-13-9P |
|    | 635712-14-0P | 635712-15-1P | 635712-16-2P |

635712-17-3P    635712-19-5P    635712-20-8P  
 635712-22-6P    635712-23-1P    635712-24-2P  
 635712-25-3P    635712-26-4P    635712-27-5P  
 635712-28-6P    635712-29-7P    635712-30-0P  
 635712-31-1P    635712-32-2P    635712-33-3P  
 635712-34-4P    635712-35-5P    635712-36-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS


CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-73-8 CAPLUS  
CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-75-0 CAPLUS  
CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-76-1 CAPLUS  
CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-(*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(trifluoromethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(1-methylethyl)phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[[[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[<sup>(1S)</sup>-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[<sup>(1S)</sup>-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-([(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-(trifluoromethoxy)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
 (9 CITINGS)  
 REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991516 CAPLUS Full-text

DOCUMENT NUMBER: 140:42208

TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists

INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Vig, Shikha

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 309 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

102a


102e

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2003104236   | A1   | 20031218 | WO 2003-US16576 | 20030527 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| CA 2487976  | A1   | 20031218 | CA 2003-2487976 | 20030527 |
| AU 2003237255   | A1   | 20031222 | AU 2003-237255  | 20030527 |
| BR 2003011812   | A    | 20050329 | BR 2003-11812   | 20030527 |
| EP 1539766  | A1   | 20050615 | EP 2003-736721  | 20030527 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  |      |          |                 |          |

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 CN 1671711 A 20050921 CN 2003-818475 20030527  
 JP 2005538959 T 20051222 JP 2004-511306 20030527  
 NZ 537315 A 20060428 NZ 2003-537315 20030527  
 RU 2341526 C2 20081220 RU 2004-139061 20030527  
 NO 2004005219 A 20050228 NO 2004-5219 20041129  
 ZA 2004009654 A 20060726 ZA 2004-9654 20041129  
 MX 2004011960 A 20050331 MX 2004-11960 20041130  
 IN 2004DN03814 A 20070427 IN 2004-DN3814 20041201  
 PRIORITY APPLN. INFO.: US 2002-386138P P 20020605  
                           US 2002-388617P P 20020613  
                           US 2002-389870P P 20020619  
                           US 2002-393200P P 20020701  
                           US 2002-413534P P 20020925  
                           WO 2003-US16576 W 20030527

OTHER SOURCE(S): MARPAT 140:42208  
 GI



AB Diazaheterocycles I [m, n = 0-2; m .noteq. n = 2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic] were prep'd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assoc'd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prep'd. from 1H-indazole-5-carboxaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .ltoreq. 10 nM.

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 635711-71-6P | 635711-72-7P | 635711-73-8P |
|    | 635711-75-0P | 635711-76-1P | 635711-77-2P |
|    | 635711-78-3P | 635711-79-4P | 635711-80-7P |
|    | 635711-82-9P | 635711-83-0P | 635711-84-1P |
|    | 635711-86-3P | 635711-87-4P | 635711-88-5P |
|    | 635711-89-6P | 635711-90-9P | 635711-92-1P |
|    | 635711-93-2P | 635711-94-3P | 635711-95-4P |
|    | 635711-96-5P | 635711-97-6P | 635711-98-7P |
|    | 635711-99-8P | 635712-00-4P | 635712-01-5P |
|    | 635712-02-6P | 635712-04-8P | 635712-05-9P |
|    | 635712-08-2P | 635712-09-3P | 635712-10-6P |
|    | 635712-11-7P | 635712-12-8P | 635712-13-9P |

635712-14-0P    635712-15-1P    635712-16-2P  
 635712-17-3P    635712-19-5P    635712-20-8P  
 635712-22-0P    635712-23-1P    635712-24-2P  
 635712-25-3P    635712-26-4P    635712-27-5P  
 635712-28-6P    635712-29-7P    635712-30-0P  
 635712-31-1P    635712-32-2P    635712-33-3P  
 635712-34-4P    635712-35-5P    635712-36-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-71-6 CAPLUS

CN Urea, N-[<sup>(1S)</sup>-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[<sup>(1S)</sup>-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-(*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[*(1S)*-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-[trifluoromethyl]phenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(1-methylethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[ $(1S)$ -1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[[[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[<sup>(1S)</sup>-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[<sup>(1S)</sup>-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-([(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-((1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-(trifluoromethoxy)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:76556 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 138:131125  
 TITLE: Fat accumulation-modulating compounds  
 INVENTOR(S): Stevenson, Michael John; Leighton, Harry Jefferson  
 PATENT ASSIGNEE(S): Adipogenix, Inc., USA  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2003007888   | A2   | 20030130 | WO 2002-US23295 | 20020722   |
| WO 2003007888   | A3   | 20031127 |                 |            |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CL, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| AU 2002322585   | A1   | 20030303 | AU 2002-322585  | 20020722   |
| US 20030144350  | A1   | 20030731 | US 2002-201588  | 20020722   |
| PRIORITY APPLN. INFO.:  |      |          | US 2001-306837P | P 20010720 |
|   |      |          | WO 2002-US23295 | W 20020722 |

OTHER SOURCE(S): MARPAT 138:131125  
 GI



- AB The present invention pertains to compds. effective at modulating fatty acid or triglyceride ("fat") accumulation by cells, such compds. having therapeutic potential as regulators of body mass and for the treatment of overweight individuals, obesity, and metabolic disorders. An example compd. is I and protocol for high-throughput screening of compd. efficacy on human preadipocytes is given. Therapeutic methods and pharmaceutical compns. featuring these compds. are also provided.
- IT 491868-44-1  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fat accumulation-modulating compds.)
- RN 491868-44-1 CAPLUS
- CN Urea, N-[3-[4-(1H-benzimidazol-2-yl)-1-piperidinyl]-3-oxopropyl]-N'-[3,5-bis(trifluoromethyl)phenyl]-N-cyclohexyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(8 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2001:507689 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 135:92860  
TITLE: Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders  
INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander;  
Muller, Stephan Georg; Doods, Henri; Bauer, Eckhart  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
SOURCE: [PCT Int. Appl.](#), 153 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE            |
|---|------|----------|------------------|-----------------|
| WO 2001049676   | A1   | 20010712 | WO 2000-EP13236  | <u>20001222</u> |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW |      |          |                  |                 |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |                 |
| DE 19963868   | A1   | 20010712 | DE 1999-19963868 | 19991230        |
| CA 2395541  | A1   | 20010712 | CA 2000-2395541  | 20001222        |
| CA 2395541  | C    | 20080923 |                  |                 |
| BR 2000017063   | A    | 20021022 | BR 2000-17063    | 20001222        |
| EP 1252153  | A1   | 20021030 | EP 2000-991806   | 20001222        |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |      |          |                  |                 |
| HU 2003000002   | A2   | 20030528 | HU 2003-2        | 20001222        |
| HU 2003000002   | A3   | 20060130 |                  |                 |
| JP 2003519222   | T    | 20030617 | JP 2001-550216   | 20001222        |
| EE 200200369  | A    | 20031015 | EE 2002-369      | 20001222        |
| CN 1203069  | C    | 20050525 | CN 2000-818106   | 20001222        |
| AU 783275   | B2   | 20051006 | AU 2001-35379    | 20001222        |
| NZ 519939   | A    | 20060831 | NZ 2000-519939   | 20001222        |
| IL 150377   | A    | 20070617 | IL 2000-150377   | 20001222        |
| TW 255267   | B    | 20060521 | TW 2000-89128135 | 20001228        |
| IN 2002MN00796  | A    | 20050304 | IN 2002-MN796    | 20020614        |
| BG 106848   | A    | 20021229 | BG 2002-106848   | 20020620        |
| ZA 2002005181   | A    | 20030930 | ZA 2002-5181     | 20020627        |
| NO 2002003161   | A    | 20020628 | NO 2002-3161     | 20020628        |
| NO 323700   | B1   | 20070625 |                  |                 |
| MX 2002006509   | A    | 20021129 | MX 2002-6509     | 20020628        |
| US 20030212057  | A1   | 20031113 | US 2002-169009   | 20021107        |
| US 6949541  | B2   | 20050927 |                  |                 |
| HK 1054026  | A1   | 20050916 | HK 2003-106237   | 20030901        |
| IN 2007MN00174  | A    | 20070817 | IN 2007-MN174    | 20070202        |
| PRIORITY APPLN. INFO.:  |      |          | DE 1999-19963868 | A 19991230      |
|   |      |          | WO 2000-EP13236  | W 20001222      |
|   |      |          | IN 2002-MN796    | A3 20020614     |

OTHER SOURCE(S):

MARPAT 135:92860

GI



AB The invention relates to piperidine-substituted .alpha.- or .beta.-amino acids [(I); R = (un)satd. (un)substituted heterocycle; R1 = Ph, naphthyl, (un)substituted heterocycle; R2 = H, alkyl; A, A1 = H; when one of A or A1 = H, the other = NH2, 1,4'-bipiperidyl, alkylamino, N(R3)(Z-R4) (forming


(substituted) .alpha.- or .beta.-amino acid); R3 = H, alkyl; Z = C(O), SO<sub>2</sub>; R4 = alkoxy, amino, (di)alkylamino, substituted heterocycle] their tautomers, diastereomers, enantiomers, mixts., and to their salts, in particular, their physiol. compatible salts with inorg. or org. acids or bases, which comprise valuable pharmacol. properties, in particular, CGRP-antagonistic properties. The invention also relates to medicaments contg. these compds., to their use and to methods for the prodn. thereof; formulations were given. Prepn. of fragments CO<sub>2</sub>HC(R<sub>2</sub>)AC(O)R<sub>1</sub>, and A or A<sub>1</sub> substituents were given. Thus (R,S)-4-(4-amino-3,5-dibromophenyl)-2- [(1,1-dimethylethoxy carbonyl)methylamino]-4-oxo-butanoic acid was reacted with 3-(piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one to give I (R = 1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one; R<sub>1</sub> = 4-amino-3,5-dibromophenyl; R<sub>2</sub> = H; A = (1,1-dimethylethoxy carbonyl)methylamino; A<sub>1</sub> = H). In in vitro tests using SK-N-MC cells as tests of human CGRP-receptor binding affinity, I had IC<sub>50</sub> < 10000 nM, and acted as CGRP antagonists at dosages between 10<sup>-11</sup> - 10<sup>-5</sup> M.

IT 349535-73-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders)

RN 349535-73-5 CAPLUS

CN Urea, N-[3-(4-amino-3,5-dibromophenyl)-3-oxo-1-[(4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)carbonyl]propyl]-N'-2-pyridinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:761524 CAPLUS Full-text  
DOCUMENT NUMBER: 132:12331  
TITLE: Tricyclic antitumor farnesyl protein transferase inhibitors  
INVENTOR(S): Njoroge, F. George; Doll, Ronald J.; Remiszewski, Stacy W.  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: U.S., 55 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE        |
|------------------------|------|----------|-----------------|-------------|
| US 5994364             | A    | 19991130 | US 1997-927467  | 19970911    |
| US 6277854             | B1   | 20010821 | US 1999-352895  | 19990713    |
| PRIORITY APPLN. INFO.: |      |          | US 1996-25872P  | P 19960913  |
|                        |      |          | US 1997-49848P  | P 19970617  |
|                        |      |          | US 1997-927467  | A3 19970911 |

OTHER SOURCE(S): MARPAT 132:12331  
GI




- AB The title compds. I [X = CH, C; one of a, b, c, d = N, NR<sub>9</sub> and the others = CR<sub>1</sub>, CR<sub>2</sub> or each of a, b, c, d = CR<sub>1</sub> or CR<sub>2</sub>; R<sub>1</sub> = H, R<sub>2</sub> = Br, R<sub>3</sub>, R<sub>4</sub> = Br, Cl; R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> = H, CF<sub>3</sub>, alkyl, aryl, etc.; m = 0-5; n = 0, 1; Y = NR<sub>21</sub>R<sub>22</sub> and R<sub>21</sub>, R<sub>22</sub> = H, alkyl, benzyl, etc.; or NR<sub>21</sub>R<sub>22</sub> = pyrrolidino, piperidino, etc.], antitumor farnesyl protein transferase inhibitors, were prepd. E.g., (+)-N-[2-[4-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidinyl]-2-oxoethyl]urea was prepd.
- IT 251365-92-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of tricyclic antitumor farnesyl protein transferase inhibitors)
- RN 251365-92-1 CAPLUS
- CN Urea, N-[4-[4-[(11R)-3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-4-oxobutyl]-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
 (4 CITINGS)  
 REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:234515 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 131:31909  
 TITLE: Synthesis of a Series of Stromelysin-Selective  
 Thiadiazole Urea Matrix Metalloproteinase Inhibitors  
 Jacobsen, E. Jon; Mitchell, Mark A.; Hedges, Susan  
 K.; Belonga, Kenneth L.; Skaletzky, Louis L.; Stelzer,  
 Lindsay S.; Lindberg, Thomas J.; Fritzen, Edward L.;  
 Schostarez, Heinrich J.; O'Sullivan, Theresa J.;  
 Maggiora, Linda L.; Stuchly, Christopher W.; Laborde,  
 Alice L.; Kubicek, Marc F.; Poorman, Roger A.; Beck,  
 Joan M.; Miller, Henry R.; Petzold, Gary L.; Scott,  
 Pam S.; Truesdell, Scott E.; Wallace, Tanya L.; Wilks,  
 John W.; Fisher, Christopher; Goodman, Linda V.;  
 Kaytes, Paul S.; Ledbetter, Stephen R.; Powers, Elaine  
 A.; Vogeli, Gabriel; Mott, John E.; Trepod, Catherine  
 M.; Staples, Douglas J.; Baldwin, Eric T.; Finzel,  
 Barry C.  
 CORPORATE SOURCE: Departments of Structural Analytical and Medicinal  
 Chemistry Protein Science Genomics Discovery  
 Technologies Cell and Molecular Biology and Chemical  
 Process Research Preparations, Pharmacia Upjohn,  
 Kalamazoo, MI, 49007, USA  
 SOURCE: Journal of Medicinal Chemistry (1999), 42(9),  
 1525-1536  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 131:31909  
 GI



AB The synthesis and enzyme inhibition data for a series of thiadiazole urea matrix metalloproteinase inhibitors are described. A broad screening effort was utilized to identify several thiadiazoles which were weak inhibitors of stromelysin. Optimization of the thiadiazole leads to include an .alpha.-amino acid side chain with variable terminal amide substituents provided a series of ureas which were moderately effective stromelysin inhibitors, with Ki's between 0.3 and 1.0 .mu.M. The most effective analogs utilized an L-phenylalanine as the amino acid component. In particular, unsubstituted I (R1 = Ph, R2 = NHMe) had a Ki of 710 nM, while I (R1 = p-fluorophenyl, R2 = NHMe) displayed increased potency (100 nM). Stromelysin inhibition was further improved using a pentafluorophenylalanine substituent which resulted in I (R1 = C6F5, R2 = NHMe), a 14 nM inhibitor. While gelatinase inhibition was generally poor, the use of 1-(2-pyridyl)piperazine as the amide component usually provided for enhanced activity, with I [R1 = C6F5, R2 = 4-(2-pyridyl)-1-piperazinyl] inhibiting gelatinase with a Ki of 770 nM. The combination of this heterocycle with a p-fluorophenylalanine substituent provided the only analog, I [R1 = p-fluorophenyl, R2 = 4-(2-pyridyl)-1-piperazinyl], with collagenase activity (13 .mu.M). The SAR for analogs described within this series can be rationalized through consideration of the x-ray structure recently attained for I (R1 = C6F5, R2 = NHMe) complexed to stromelysin. Uniquely, this structure showed the inhibitor to be completely oriented on the left side of the enzyme cleft. These results suggest that thiadiazole urea heterocycles which incorporate a substituted phenylalanine can provide selective inhibitors of stromelysin. Careful selection of the amide substituent can also provide for analogs with modest gelatinase inhibition.

IT 198700-71-9P 198700-78-6P 198700-79-7P

198700-83-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-78-6 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-'[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-83-3 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-'[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



|                      |    |   |
|----------------------|----|---|
| OS.CITING REF COUNT: | 38 | THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)                                    |
| REFERENCE COUNT:     | 39 | THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:788775 CAPLUS Full-text

DOCUMENT NUMBER: 130:38702

TITLE: Preparation of thiadiazole derivatives useful for the treatment of diseases related to connective tissue

INVENTOR(S): degradation  
 Jacobsen, Eric J.; Mitchell, Mark A.; Schostarez,  
 Heinrich J.; Harper, Donald E.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: U.S., 29 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE     |
|------------------------|------|----------|-----------------|----------|
| US 5847148             | A    | 19981208 | US 1997-835599  | 19970410 |
| PRIORITY APPLN. INFO.: |      |          | US 1997-835599  | 19970410 |

OTHER SOURCE(S): MARPAT 130:38702

AB Thiadiazole derivs. RNHC(:X)NHCHR1(CHR3)nCOR2 (R = 4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl; X = O, S; R1, R3 = H, alkyl, aralkyl, cycloalkylalkyl, alkoxyalkyl, etc.; R2 = OH, alkoxy, aryloxy, amino group; n = 0, 1) were prepd. for inhibition of various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and thus are useful for the treatment of matrix metallo endoproteinase diseases. Thus, N-[[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]carbonyl]-L- phenylalanine Me ester, prepd. by reaction of L-phenylalanine Me ester hydrochloride with phosgene and 5-amino-1,3,4-thiadiazole-2-thiol, showed Ki = 0.9 .mu.M for inhibition of stromelysin.


IT 198700-71-9P 198700-78-6P 198700-79-7P  
 198700-83-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of thiadiazole amino acid derivs. for treatment of diseases related to connective tissue degrdn.)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-78-6 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-'[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-83-3 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-'[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:180865 CAPLUS Full-text

DOCUMENT NUMBER: 128:230252



ORIGINAL REFERENCE NO.: 128:45607a, 45610a

TITLE: Preparation of benzocycloheptapyridines as farnesyl

INVENTOR(S): protein transferase inhibitors  
 Njoroge, F. George; Doll, Ronald J.; Remiszewski,  
 Stacy W.  
 PATENT ASSIGNEE(S): Schering Corp., USA  
 SOURCE: PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 9811092  | A1   | 19980319 | WO 1997-US15899 | 19970911   |
| W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID,<br>IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,<br>NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU |      |          |                 |            |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,<br>GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,<br>GN, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| CA 2266015  | A1   | 19980319 | CA 1997-2266015 | 19970911   |
| CA 2266015  | C    | 20031230 |                 |            |
| AU 9748011  | A    | 19980402 | AU 1997-48011   | 19970911   |
| EP 929544   | A1   | 19990721 | EP 1997-910710  | 19970911   |
| EP 929544   | B1   | 20041110 |                 |            |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,<br>LT, LV, FI, RO  |      |          |                 |            |
| CN 1238770  | A    | 19991215 | CN 1997-199602  | 19970911   |
| HU 2000001109   | A2   | 20010428 | HU 2000-1109    | 19970911   |
| JP 2001521489   | T    | 20011106 | JP 1998-513758  | 19970911   |
| AT 282036   | T    | 20041115 | AT 1997-910710  | 19970911   |
| ES 2229340  | T3   | 20050416 | ES 1997-910710  | 19970911   |
| KR 2000036111   | A    | 20000626 | KR 1999-702134  | 19990312   |
| HK 1018446  | A1   | 20050401 | HK 1999-103422  | 19990807   |
| PRIORITY APPLN. INFO.:  |      |          | US 1996-712989  | A 19960913 |
|   |      |          | US 1997-877400  | A 19970617 |
|   |      |          | WO 1997-US15899 | W 19970911 |

OTHER SOURCE(S): MARPAT 128:230252  
 GI



AB Title compds. [I; 1 of a,b,c,d = N or NR9 and the others = CR1 or CR2; A,B = halo, R10, OR11, H2, H and halo, H and alkyl, etc.; R1-R4 = H, halo, alkoxy, (di)alkylamino, etc.; R3R4 = atoms to complete a ring; R5-R8 = H, (alkoxy)alkyl, alkanoyl, aryl, etc.; R9 = oxido, Me, (CH2)nCO2H; R10 = H,


(ar)alkyl, aryl; R11 = alkyl or aryl; X = N, C, CH; n = 1-3; R = (CH<sub>2</sub>)<sub>n</sub>(CO)<sub>w</sub>Y; Y = NR<sub>21</sub>R<sub>22</sub>, alkoxy, OM; M = alkali metal atom; NR<sub>21</sub>,R<sub>22</sub> = H, (cyclo)alkyl, CH<sub>2</sub>CONH<sub>2</sub>, Ph, CH<sub>2</sub>Ph, Bz, alkylsulfonyl, NHPH, acyl, pyridyl, (dialkyl)carbamoyl, CONHPh; NR<sub>21</sub>R<sub>22</sub> = heterocyclyl] were prepd. Thus, title compd. II (R14 = H) was N-acylated with EtO<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>K to give II (R14 = COCH<sub>2</sub>CO<sub>2</sub>Et). Data for biol. activity of I were given.

IT 204761-71-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of benzocycloheptapyridines as farnesyl protein transferase inhibitors)

RN 204761-71-7 CAPLUS

CN Urea, N-[4-[4-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-4-oxobutyl]-N'-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)  
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1997:717904 CAPLUS Full-text  
DOCUMENT NUMBER: 128:3886  
ORIGINAL REFERENCE NO.: 128:843a,846a  
TITLE: Preparation of thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors  
INVENTOR(S): Jacobsen, E. Jon; Mitchell, Mark A.; Schostarez, Heinrich Joseph; Harper, Donald E.  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Jacobsen, E. Jon; Mitchell, Mark A.; Schostarez, Heinrich Joseph; Harper, Donald E.  
SOURCE: PCT Int. Appl., 85 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| WO 9740031   | A1   | 19971030 | WO 1997-US5428  | 19970410 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, |      |          |                 |          |

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,  
 VN, YU  
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
 ML, MR, NE, SN, TD, TG  
 AU 9726036 A 19971112 AU 1997-26036 19970410  
 EP 900211 A1 19990310 EP 1997-917801 19970410  
 EP 900211 B1 20030702  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI  
 JP 2000509039 T 20000718 JP 1997-538079 19970410  
 AT 244229 T 20030715 AT 1997-917801 19970410  
 ES 2202602 T3 20040401 ES 1997-917801 19970410  
 PRIORITY APPLN. INFO.: US 1996-16003P P 19960423  
 OTHER SOURCE(S): MARPAT 128:3886 WO 1997-US5428 W 19970410  
 GI



AB Novel thiadiazole derivs. I [X = O, S; R1 = H, C1-6 alkyl, (CH2)0-4-aryl, (CH2)1-4-cycloalkyl, C1-4 alkyl-OR4, C1-4 alkyl-SR4, (CH2)1-4-heteroaryl, CO2R4, CONR52, (CH2)1-4-OSiR44; R2 = OR5, NR6R7; R3 = H, C1-6 alkyl, (CH2)0-4-aryl, (CH2)0-4-cycloalkyl, C1-4 alkyl-OR4, C1-4 alkyl-SR4, OR4; R4 = H, C1-6 alkyl, (CH2)0-4-aryl; R5 = H, C1-6 alkyl, aryl; R6, R7 = independently H, C1-6 alkyl, C1-6-OR4, (CH2)0-4-aryl, (CH2)1-4-cycloalkyl, (CH2)1-4-heteroaryl, CH2Q, (CH2)1-4-CO2R4, (CH2)1-4CONR52, 5-[5-(dimethylamino)-1-naphthylsulfonyl]aminopentyl; NR6R7 = azetidino, pyrrolidino, piperidino, morpholino, 4-thiomorpholino, 4-R8-substituted piperazino; R8 = H, C1-6 alkyl, (CH2)1-4-aryl, CHPh2, (CH2)1-4-heteroaryl; Q = satd., 5- or 6-membered heterocycle contg. 1-2 N, O, or S atoms; n = 0, 1] and II (R9 = CH2Ph, CH2CH2Ph), or pharmaceutically acceptable salts thereof, are presented as inhibitors various enzymes from the matrix metalloproteinase family, predominantly stromelysins. Thus, I and II are useful for the treatment of matrix metalloendopeptidase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, and other diseases related to connective tissue degrdn. Thus, reaction of L-phenylalanine Me ester isocyanate (prepn. given) with 5-amino-1,3,4-thiadiazole-2-thiol in THF gave 58% Me ester III (R = OMe). Amidation of ester III (R = OMe) with MeNH2 gave amide III (R = NHMe). Ureas II (R = OMe, NHMe) and related compds. were tested for stromelysin inhibition, with III (R = OMe, NHMe) having Ki = 0.9 and 0.27 .mu.M, resp.  
 IT 198700-71-9P 198700-78-6P 198700-79-7P  
 198700-83-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-78-6 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-83-3 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1994:217658 CAPLUS Full-text  
DOCUMENT NUMBER: 120:217658  
ORIGINAL REFERENCE NO.: 120:38657a,38660a  
TITLE: Preparation and formulation of 2-aryl-3-(ureidoacetyl)thiazolidine-4-carboxylates and analogs as CCK receptor and gastrin receptor ligands  
INVENTOR(S): Capet, Marc; Cotrel, Claude; Guyon, Claude; Joannic, Michel; Manfre, Franco; Roussel, Gerard; Dubroeuq, Marie Christine; Cheve, Michel; Dutruc-Rosset, Gilles  
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer SA, Fr.  
SOURCE: PCT Int. Appl., 186 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE            |
|---|------|----------|-----------------|-----------------|
| WO 9301167  | A1   | 19930121 | WO 1992-FR626   | <u>19920703</u> |
| W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RU, US<br>RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE |      |          |                 |                 |
| FR 2678938  | A1   | 19930115 | FR 1991-8675    | 19910710        |
| FR 2678938  | B1   | 19931008 |                 |                 |
| EP 527069   | A1   | 19930210 | EP 1992-401904  | 19920703        |
| R: PT   |      |          |                 |                 |
| AU 9223275  | A    | 19930211 | AU 1992-23275   | 19920703        |
| AU 662345   | B2   | 19950831 |                 |                 |
| EP 593639   | A1   | 19940427 | EP 1992-915456  | 19920703        |
| EP 593639   | B1   | 19950405 |                 |                 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE   |      |          |                 |                 |
| JP 06509331   | T    | 19941020 | JP 1992-502018  | 19920703        |
| JP 3034043  | B2   | 20000417 |                 |                 |
| AT 120732   | T    | 19950415 | AT 1992-915456  | 19920703        |
| ES 2071510  | T3   | 19950616 | ES 1992-915456  | 19920703        |
| HU 70403  | A2   | 19951030 | HU 1994-61      | 19920703        |

|                        |    |          |                 |            |
|------------------------|----|----------|-----------------|------------|
| HU 223470              | B1 | 20040728 |                 |            |
| PL 171054              | B1 | 19970228 | PL 1992-313380  | 19920703   |
| PL 171094              | B1 | 19970328 | PL 1992-313379  | 19920703   |
| PL 171112              | B1 | 19970328 | PL 1992-313381  | 19920703   |
| PL 171095              | B1 | 19970328 | PL 1992-313382  | 19920703   |
| PL 171333              | B1 | 19970430 | PL 1992-302029  | 19920703   |
| CZ 283602              | B6 | 19980513 | CZ 1994-49      | 19920703   |
| RU 2118316             | C1 | 19980827 | RU 1994-15258   | 19920703   |
| CA 2102697             | C  | 20030930 | CA 1992-2102697 | 19920703   |
| ZA 9205128             | A  | 19930428 | ZA 1992-5128    | 19920709   |
| NO 9304300             | A  | 19931126 | NO 1993-4300    | 19931126   |
| NO 180166              | B  | 19961118 |                 |            |
| NO 180166              | C  | 19970226 |                 |            |
| FI 105190              | B1 | 20000630 | FI 1994-72      | 19940107   |
| US 5610144             | A  | 19970311 | US 1994-175381  | 19940627   |
| PRIORITY APPLN. INFO.: |    |          | FR 1991-8675    | A 19910710 |
|                        |    |          | WO 1992-FR626   | A 19920703 |

OTHER SOURCE(S): MARPAT 120:217658  
GI



AB Title compds. [I; Z = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, SOO-2, CHOH and R<sub>1</sub> = (substituted)(hetero)aryl; Z = CH<sub>2</sub>, R<sub>1</sub> = H, and R<sub>5</sub> = Ph; Z = CHPh and R<sub>1</sub> = R<sub>5</sub> = H; R<sub>2</sub> = alkoxy carbonyl, CONH<sub>2</sub>, Ph, etc.; R<sub>3</sub> = (substituted) phenylamino, Ph, etc.; R<sub>4</sub> = H, alkyl] were prepd. Thus, L-HSCH<sub>2</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H was cyclocondensed with PhCHO and the esterified product N-acetylated with Me<sub>3</sub>CO<sub>2</sub>CNHCH<sub>2</sub>CO<sub>2</sub>H to give, after silica chromatog. and deprotection, thiazolidinecarboxylate (2R,4R)-II (III; R = H). The latter was condensed with 3-MeC<sub>6</sub>H<sub>4</sub>NCO to give III (R = CONHC<sub>6</sub>H<sub>4</sub>Me-3). I had IC<sub>50</sub> .1toreq. 1 mM for inhibition of binding at CCK receptors. Prep. of a chiral HPLC phase for optical resoln. of I is given.

IT 153242-87-6P    153243-31-3P    153243-32-4P

153244-03-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of CCK and gastrin receptor ligand)

RN 153242-87-6 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 2-(3-pyridinyl)-3-[[[[[3-[[(2-trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]amino]acetyl]-, 1,1-dimethylethyl ester, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153243-31-3 CAPLUS

CN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[3-[(2-(trimethylsilyl)ethoxy]carbonyl)phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153243-32-4 CAPLUS

CN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[3-[(2-(trimethylsilyl)ethoxy]carbonyl)phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153244-03-2 CAPLUS

CN D-Proline, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-5-

(2-pyridinyl)-, 1,1-dimethylethyl ester, (5S)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 153241-68-0P 153241-89-5P 153241-90-8P  
153242-19-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as CCK and gastrin receptor ligand)

RN 153241-68-0 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 3-[[(3-  
carboxyphenyl)amino]carbonyl]amino]acetyl]-2-(3-pyridinyl)-,  
4-(1,1-dimethylethyl) ester, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153241-89-5 CAPLUS

CN L-Proline, 1-[N-[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-  
yl)-, 2-(1,1-dimethylethyl) ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153241-90-8 CAPLUS

CN L-Proline, 1-[N-[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153242-19-4 CAPLUS

CN D-Proline, N-[(3-carboxyphenyl)amino]carbonyl]glycyl-5-(2-pyridinyl)-, 2-(1,1-dimethylethyl) ester, (5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT:

14

THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>

Executing the logoff script...

=> LOG H

| COST IN U.S. DOLLARS                       | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST                        | 114.30           | 313.84        |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE                        | -16.40           | -16.40        |

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 11:20:28 ON 21 SEP 2009